Our leadership team has extensive experience in developing RNA therapeutics and building successful biopharmaceutical companies.
Paris most recently served as President and CEO of ARIAD Pharmaceuticals through its acquisition by Takeda in 2017. Prior to ARIAD, Paris was President of EMD Serono, the North American biopharmaceutical business of Merck KGaA, as well as President of Merck Serono in Japan and the Serono Research & Development Institute. He has led partnerships with Pfizer, Bristol Myers Squibb, Eli Lilly & Co., Dainippon Sumitomo Pharma, Mitsubishi Tanabe, Otsuka, Incyte, and others.
Bo Rode Hansen, MBA, PhD
President and Chief Executive Officer
Bo joined Genevant from Roche, where he served as Global Head of RNA Therapeutics and General Manager of the Roche Innovation Center Copenhagen. Prior to Roche, Bo was Executive Vice President and Head of Drug Discovery & Alliance Management at Santaris Pharma A/S through the company’s acquisition by Roche in 2014. Over the course of his career, Bo has led over 50 RNA therapeutic discovery programs which have yielded 10 clinical candidates and over 40 patents and patent applications.
Elizabeth A. Czerepak
Chief Financial Officer and Chief Business Officer
Elizabeth has had an extensive career in big pharma and biotechnology, and as a venture capital investor. For 18 years at Merck & Co., Hoffmann-La Roche and BASF (Knoll) Pharma she held executive positions in finance, business development and corporate development, serving a primary role in Roche’s $5.4bn acquisition of Syntex and BASF Pharma’s $6.9bn sale to Abbott. Later, as Managing Director and General Partner of the BSHI venture fund at JPMorgan and Bear Stearns, she led investments in thirteen biotech companies. Most recently, Elizabeth served as CFO of two public and one private biotech companies.
Margrit Schwarz, MBA, PhD
Chief Scientific Officer and Head of R&D
Margrit Schwarz, joins Genevant from Roche Pharmaceuticals, Basel, Switzerland, where she was Vice President and Global Head, External Innovation. Prior to the engagement at Roche, Dr. Schwarz held appointments as VP and Therapeutic Area Head at Boehringer Ingelheim, Ridgefield, CT, and Director Research at Amgen, South San Francisco, CA. At both companies, she has successfully built preclinical pipelines for cardiometabolic diseases and dyslipidemia, with five drug candidates advanced into clinical development under her tenure, including an anti-PCSK9 mAb launched in 2015 as Repatha for the treatment of hypercholesterolemia. Prior to joining Amgen, Dr. Schwarz held scientific leadership roles in discovery research at F. Hoffmann-La Roche, Basel, and at Tularik, South San Francisco. She holds a PhD in Biochemistry from the University of Cologne, Germany and an MBA from Columbia University, New York, and is the author of numerous publications and several issued patents.
Pete Zorn, JD
Chief Operating Officer
Pete Zorn served most recently as Chief Corporate Officer and General Counsel at Albireo Pharma where he led the corporate development, legal, corporate communications and human resource functions. While at Albireo, Mr. Zorn successfully negotiated and executed the strategic share exchange that resulted in its becoming a public company, as well as several other value-creating transactions. Previously, he was General Counsel and Vice President, Communications at Santaris Pharma, an RNA therapeutics company acquired by Roche, and Senior Vice President and General Counsel at Targacept, where he was instrumental in a variety of significant milestones, including its company-launching spinout, IPO and additional financings, business operations achievements and multiple complex collaborations with major pharmaceutical companies. Mr. Zorn began his career at a large law firm in North Carolina and received his undergraduate degree with honors from Harvard and his law degree with honors from the University of North Carolina at Chapel Hill.
Peter Lutwyche, PhD
Chief Technology Officer & Vancouver Site Head
Peter most recently served as Chief Technology Officer at Arbutus Biopharma Corporation where he led the development of the company’s nucleic acid-delivery technology. Earlier in his career, he was Head of Pharmaceutical Development at QLT where he contributed to the development and commercialization of VISUDYNE®. Peter has over 20 years of experience in the field of nucleic acid-based products.
James Heyes, PhD
SVP, Technology Development
James brings expertise in lipid chemistry and nucleic acid drug delivery with over 17 years of experience in the field. He is a key inventor of next generation lipid nanoparticle and ligand conjugate technology, with more than 20 issued and published U.S. patents in the area. He designed the lipid components enabling the first demonstration of RNA interference in primates, and subsequently the advance of 13 clinical candidates. As Vice President of Drug Delivery at Arbutus, he led a multidisciplinary team spanning early discovery to pharmaceutical development.
Vice President, People & Culture
Janielle brings over 20 years of experience focused on global people topics within the health, bioscience, and the financial services industries. Throughout her career, Janielle led and coached companies through rapid organic and inorganic growth, while helping them build or strengthen their capabilities to attract, motivate, and retain talent that delivers on business outcomes. Along with her consulting practice supporting biotech startups, Janielle has also worked for Thermo Fisher Scientific, the U.S. affiliates of Merck KGaA Darmstadt, EMD Serono and MilliporeSigma, and Covidien/Medtronic.